Previous 10 | Next 10 |
home / stock / alpmf / alpmf news
2023-03-15 09:10:29 ET The Biden administration on Wednesday published a list of 27 Medicare Part B drugs that will be subject to inflation penalties for the first time in the U.S., including some key pipeline products from AbbVie ( ABBV ), Gilead ( GILD ), and Seagen ( SGEN ...
2023-03-13 08:07:25 ET Bristol Myers ( NYSE: BMY ), Pfizer ( NYSE: PFE ), and AbbVie ( NYSE: ABBV ) are among firms likely to face Medicare price negotiations for some of the key blockbuster medications, Reuters reported Monday, citing five Wall Street and ac...
2023-03-05 12:00:42 ET Cancer drugmaker Seagen ( NASDAQ: SGEN ) had reportedly drawn interest from two pharma giants in less than a year, indicating a bidding war not seen since Horizon Therapeutics ( HZNP ) sparked a buyout fight which Amgen ( AMGN ) won in late 2022. ...
Merck ( NYSE: MRK ) is discontinuing a phase 3 trial of a Keytruda combination treatment for prostate cancer after the study failed its main goals, while another late stage trial of the blockbuster drug did not meet its main objectives to treat a type of lung cancer. Prostate c...
Summary Astellas came in with a mixed set of results, with growth across product segments balanced by challenges in U.S. sales. We are unsure about generic competitors posing a threat to XTANDI's market share. Profitability and economic profit continue to remain a standout, despite ...
The following slide deck was published by Astellas Pharma Inc. in conjunction with their 2023 Q3 earnings call. For further details see: Astellas Pharma Inc. 2023 Q3 - Results - Earnings Call Presentation
Astellas Pharma ( OTCPK:ALPMF ): Q3 GAAP EPS of ¥103.61. Revenue of ¥1.17B. For further details see: Astellas Pharma GAAP EPS of ¥103.61, revenue of ¥1.17B
Summary Taysha has a good chance of scoring with the GAN indication. Astellas may license this program if that happens. However, the FDA's request for more patients is a critical problem. Since its IPO in September 2020, Taysha Gene Therapies ( TSHA ) stock price has b...
The US FDA has accepted supplemental Biologics License Applications from Merck ( NYSE: MRK ), Seagen ( NASDAQ: SGEN ), and Astellas ( OTCPK:ALPMF )( OTCPK:ALPMY ) for a combination of Keytruda (pembrolizumab) and Padcev (enfortumab vedotin) for urotheli...
Astellas Pharma Inc. (ALPMF) Q3 2022 Earnings Conference Call October 31, 2022 04:00 a.m. ET Company Representatives Kenji Yasukawa - Chief Executive Officer Yoshitsugu Shitaka - CScO, Chief Scientific Officer Minoru Kikuoka - Chief Financial Officer Tadaaki ...
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc Company Name:
ALPMF Stock Symbol:
OTCMKTS Market:
Pharmaceutical stocks were initially expected to be largely immune to the COVID-19 economic downturn. Drugmakers, after all, generally produce products that are essential to daily life. However, the extreme social distancing that has become part and parcel of this unusual period has halted nume...
One of England's top healthcare watchdogs, the National Institute for Health and Care Excellence (NICE), has officially decided to stay the course and reject AstraZeneca 's (NYSE: AZN) lung cancer drug Tagrisso. A few months ago, the pharmaceutical giant argued that the drug should receive...
This past year proved profitable for investors in Incyte (NASDAQ: INCY) and Seattle Genetics (NASDAQ: SGEN) . Handily beating broad market and biotech indexes, these two drug manufacturers hit the $20 billion valuation mark and are poised to continue growing in the coming year -- unless, ...